Abstract
Major, well-controlled trials of Vigabatrin for infantile spasms in Europe, Canada, and the Unites States are reviewed, including dose recommendations.
Highlights
Vigabatrin is recommended as first-choice treatment of infantile spasms caused by tuberous sclerosis
In the UK Infantile Spasm Study comparing vigabatrin (100-150 mg/kg/day) with hormonal treatment, hormonal treatments were superior to vigabatrin in control of spasms; adverse events were common with both forms of therapy
Clinical benefits of vigabatrin must be balanced with associated risk of peripheral visual field defects
Summary
Well-controlled trials of Vigabatrin for infantile spasms in Europe, Canada, and the Unites States are reviewed, including dose recommendations. If the infant has not shown clinical improvement in 2 weeks, vigabatrin is discontinued and alternate treatment initiated. Treatment duration up to 6 months controlled seizures while limiting potential risks of adverse events and seizure recurrence.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
